24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros Download PDF Post navigationPreviousPrevious post:Implementation of a new strategy and launch of a capital increaseNextNext post:Presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingRelated PostsAB Science webcast of March 4, 2024March 4, 2024AB Science webcast – Masitinib in Sickle Cell DiseaseNovember 30, 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023Revenues for the first half of 2023 and update on AB Science’s activitiesSeptember 29, 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
